G42 Long Term Safety and Efficacy of Single Dose Parenteral Iron in Children with Inflammatory Bowel Disease in a Large Tertiary Centre
March 2018
Studysummary This study investigated the safety and efficacy of IV iron maltoside 1000 in treating iron-deficiency anemia among children with IBD and found a significant increase in hemoglobin levels by 6 weeks, maintained for up to a year, with minimal side effects reported.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study evaluated the long-term safety and efficacy of single-dose parenteral iron (IV iron maltoside 1000, Monofer) in 29 children with inflammatory bowel disease (IBD) who had iron-deficiency anaemia. The results showed a significant increase in mean haemoglobin levels by 6 weeks post-treatment, which remained stable up to 1 year. Only one patient experienced an acute allergic reaction, and two patients reported hair loss at 3 months, which was unlikely due to iron overload. No cases of dysmetabolic iron overload syndrome (DIOS) were observed, and liver function tests remained normal. The study concluded that parenteral iron was effective and safe for treating iron deficiency anaemia in children with IBD, with a low immediate reaction rate of 3.7%.
